GlobeNewswire

Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
03/11/2026
THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced [...]
Treace to Present at the Stifel 2026 Healthcare Conference
03/11/2026
PONTE VEDRA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Ceribell Reports Third Quarter 2026 Financial Results
03/11/2026
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
03/11/2026
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
Tarsus Reports Third Quarter 2026 Financial Results
03/11/2026
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product [...]
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2026
03/11/2026
DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
03/11/2026
$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA 45% increase in total net revenue over Q3 2025 Operational execution fueled strong cash position of $270.9 million Company to host [...]
RxSight, Inc. Reports Third Quarter 2026 Results
03/11/2026
ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Total revenue of $24 [...]
Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026
03/11/2026
SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and [...]
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
03/11/2026
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to three new employees. Effective November 1, 2026, in [...]
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
03/11/2026
Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026 [...]
HealthEquity Schedules Third Quarter Earnings Release Date
03/11/2026
DRAPER, Utah, Nov. 03, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026
Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease [...]
Crescent Biopharma Announces Grants of Inducement Awards
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Elevar Therapeutics Announces Lirafugratinib (Lyrfigtu) Added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as Second-line Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
03/11/2026
FORT LEE, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum